Biotest AG
BIESFOTCHealthcare
$32.00
+$0.00(+0.00%)
Market Cap$1.6B
P/E Ratio—
52W High$32
52W Low$30.48
Biotest AG（BIESF）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BIESF · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.03B | $0.13B | $0.03B | ($0.06B) | ($0.03B) |
| Depreciation & Amort. | $0.04B | $0.04B | $0.04B | $0.03B | $0.03B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.00B) | ($0.17B) | ($0.05B) | $0.02B | ($0.03B) |
| Net Cash from Operations | $0.06B | ($0.00B) | ($0.04B) | $0.03B | ($0.02B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.03B) | ($0.03B) | ($0.03B) | ($0.02B) | ($0.03B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Net Cash from Investing | ($0.03B) | $0.00B | ($0.04B) | ($0.02B) | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Debt Issued / Repaid | ($0.03B) | ($0.01B) | $0.10B | $0.02B | $0.05B |
| Net Cash from Financing | ($0.04B) | ($0.01B) | $0.09B | $0.02B | $0.04B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.03B | ($0.04B) | ($0.07B) | $0.02B | ($0.04B) |
| FCF Margin %(computed) | 4.43% | -5.27% | -13.52% | 3.04% | -9.03% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · EUR · B
深入了解Biotest AG
关于Biotest AG（BIESF）现金流量表
Biotest AG 2024财年经营活动现金流$0.06B，自由现金流$0.03B（FCF利润率4.43%），资本支出($0.03B)。
常见问题
BIESF · 4 问Biotest AG 2024财年自由现金流$0.03B，同比up189.2%。
BIESF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10